Gut microbiomes and treatment-resistant ulcerative colitis: a case-control study using qPCR.

Area of Science:

• Gastroenterology
• Microbiology
• Immunology

Background:

• The gut microbiome plays a pivotal role in ulcerative colitis (UC) pathogenesis and progression.
• Understanding the gut microbiome's function in refractory UC is crucial for developing effective treatment strategies.
• This study investigates microbial differences in patients with varying UC severity and their relatives.

Purpose of the Study:

• To explore the role of gut bacteria in patients with refractory ulcerative colitis (UC).
• To compare the gut microbiome composition between newly diagnosed UC patients, treatment-resistant UC patients, and their healthy relatives.
• To identify potential microbial biomarkers associated with UC treatment response.

Main Methods:

• A case-control study involving four groups: new UC patients (n=24), treatment-resistant UC patients (n=23), relatives of new UC patients (n=24), and relatives of treatment-resistant UC patients (n=23).
• Stool samples were analyzed using quantitative real-time PCR (qPCR) and culture.
• Data on probiotic consumption and antibiotic use were collected via questionnaires.

Main Results:

• No pathogenic bacteria were detected in any group.
• A significant relationship was observed between specific microbial populations (E. coli, Bifidobacterium ssp.) in treatment-resistant UC patients and their relatives (Groups 2 and 4).
• Significant differences in Lactobacillus ssp., Bifidobacterium ssp., and Bacteroides ssp. were found between newly diagnosed UC patients and treatment-resistant UC patients (Groups 1 and 2).

Conclusions:

• Intestinal microbiome composition significantly impacts ulcerative colitis management.
• Microbiome differences between treatment-resistant and newly diagnosed UC patients offer insights into treatment variability.
• Findings suggest potential for microbiome-based therapies, including fecal microbiome transplantation (FMT), probiotics, and prebiotics, for UC.